Date: 2018-05-02
Type of information: Nomination
Compound: chief operating officer - senior director of manufacturing
Company: LogicBio Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 2, 2018, LogicBio Therapeutics announced the appointment of Sandra Poole as chief operating officer, and Paul Herzich as senior director of manufacturing.
- Ms. Poole brings over 25 years of combined product and technology development, manufacturing, strategic alliances and general management experience in the biotechnology industry. Previously, she served as executive vice president, technical operations and commercial development at ImmunoGen, Inc. Prior to Immunogen, Ms. Poole spent more than 15 years at Genzyme in leadership roles of increasing responsibility, eventually rising to senior vice president of global biologics manufacturing. Ms. Poole is a member of the supervisory board of directors of Valneva SE. She holds a master’s and bachelor’s degree in Chemical Engineering from the University of Waterloo in Canada, is a licensed professional engineer and has completed the Executive Program in Business Management at the MIT Sloan School of Management. As chief operating officer, Ms. Poole will direct the company’s internal operations and help advance its robust portfolio of genome editing therapies.
- Mr. Herzich joins LogicBio from Pfizer’s Bamboo Therapeutics, where he served as director of clinical gene therapy manufacturing. In this role, Mr. Herzich managed facilities, compliance, and cGMP manufacturing of the company’s gene therapy products. Prior to Bamboo, he served as head of technical development manufacturing at Seqirus. Mr. Herzich holds an MBA from North Carolina State University and a bachelor’s degree in Biology from Rutgers University. In his new role as senior director of manufacturing, Herzich will establish and guide the development of manufacturing processes for LogicBio’s platform technology, GeneRide™.
Financial terms:
Latest news:
Is general: Yes
